Skip to main content

New Trends in the Design of Drugs Against Alzheimer's Disease

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

First described by Alois Alzheimer in 1907, Alzheimer's disease (AD) is the most common dementia type, affecting approximately 20 million people worldwide. As the population is getting older, AD is a growing health problem.

AD is currently treated by symptomatic drugs, the acetylcholinesterase inhibitors, based on the cholinergic hypothesis (1976).

During the past decade, advances in neurobiology have conducted to the identification of new targets. Although some of these innovative approaches tend to delay onset of AD, others are still symptomatic.

In this review, we present an overview of the several strategies and new classes of compounds against AD.

Keywords: Alzheimer; acetylcholinesterase; cholinergic; neurobiology

Document Type: Review Article

DOI: http://dx.doi.org/10.2174/0929867043364946

Affiliations: Natural and Synthetic DrugsResearch Center, Dept of Medicinal Chemistry, University of Liege, Av. De l'Hopital, 1, B36, 4000 Liege, Belgium

Publication date: July 1, 2004

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
ben/cmc/2004/00000011/00000013/art00006
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more